1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Autoimmune Partnering Terms and Agreements

Autoimmune Partnering Terms and Agreements

  • March 2015
  • -
  • Currentpartnering
  • -
  • 1000 pages

The Autoimmune Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in autoimmune partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Autoimmune partnering agreement structure
Autoimmune partnering contract documents
Top autoimmune deals by value
Most active autoimmune dealmakers

The Autoimmune Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter autoimmune partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors autoimmune technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains a comprehensive listing of all autoimmune partnering deals announced since 2010 including financial terms where available, including over 700 links to online deal records of actual autoimmune partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading autoimmune deals since 2010. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of autoimmune deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of autoimmune deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all oncology partnering deals signed and announced since 2010 with a contract attached. The chapter is organized by autoimmune deal type, stage of development and technology type focus. Each deal title links via Weblink to an online version of the deal record with the contract document.

Chapter 7 provides a comprehensive directory of all autoimmune partnering deals signed and announced since 2010. The chapter is organized by specific autoimmune therapy focus, including inflammatory bowel disease, psoriasis, endometriosis, lupus, type 1 diabetes and much more . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of autoimmune technologies and products.

Report scope

Autoimmune Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to autoimmune trends and structure of deals entered into by leading companies worldwide.

Autoimmune Partnering Terms and Agreements includes:

Trends in autoimmune dealmaking in the biopharma industry since 2010
Analysis of autoimmune deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life oncology deals
Access to over 700 autoimmune deals since 2010 and contract documents where available
The leading autoimmune deals by value since 2010
Most active autoimmune dealmakers since 2010
The leading autoimmune partnering resources

In Autoimmune Partnering Terms and Agreements, the available contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific autoimmune therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Autoimmune Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 autoimmune deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise autoimmune rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table Of Contents

Autoimmune Partnering Terms and Agreements
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Big pharma autoimmune dealmaking activity
2.4. Big biotech autoimmune dealmaking activity
2.5. Most active in autoimmune partnering
2.6. Autoimmune partnering by deal type
2.7. Autoimmune partnering by industry sector
2.8. Autoimmune partnering by stage of development
2.9. Autoimmune partnering by technology type
2.10. Autoimmune partnering by oncology indication
2.11. Average deal terms for autoimmune
2.11.1 Autoimmune headline values
2.11.2 Autoimmune upfront payments
2.11.3 Autoimmune milestone payments
2.11.4 Autoimmune royalty rates

Chapter 3 - Leading autoimmune deals

3.1. Introduction
3.2. Top autoimmune deals by value

Chapter 4 - Big pharma autoimmune deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma autoimmune partnering company profiles

Chapter 5 - Big biotech autoimmune deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech autoimmune partnering company profiles

Chapter 6 - Autoimmune partnering contracts directory

6.1. Introduction

6.2. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
Warranty

6.3. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.4. By technology type

Adjuvant
Analysis
Antibodies
Assays
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Blood products
Cell culture
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Implant
Industrial chemicals
In vitro models
Microarray
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines

Chapter 7 - Autoimmune dealmaking by indication

7.1. Introduction
7.2. Deals by therapeutic indication
Autoimmune
CNS: Multiple sclerosis
CNS: Restless leg syndrome
Dermatology: Eczema
Hair disorders: Alopecia
Dermatology: Psoriasis
Gastrointestinal: Celiac disease
Gastrointestinal: Inflammatory bowel disease
Gastrointestinal: Inflammatory bowel disease > Crohn's disease
Gastrointestinal: Inflammatory bowel disease > Ulcerative colitis
Genitourinary: Renal infections > Glomerulonephritis
Gynecology: Endometriosis
Hematology: Immune thrombocytopenic purpura
Hematology: Neutropenia
Immunology: Graft versus host disease
Immunology: Scleroderma
Immunology: Systemic lupus erythematosus
Metabolic: Addison's disease
Metabolic: Diabetes > Type 1
Musculoskeletal: Ankylosing spondylitis
Musculoskeletal: Juvenile arthritis
Musculoskeletal: Psoriatic arthritis
Musculoskeletal: Rheumatoid arthritis
Ophthalmics: Uveitis
Psychiatry: Sleep disorders > Narcolepsy
Respiratory: Idiopathic pulmonary fibrosis
Respiratory: Sarcoidosis
Sensory organs: Hearing disorders > Meniere's disease
Other autoimmune diseases

Chapter 8 - Partnering resource center

8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Therapy Reports

Appendices

Appendix 1: Directory of autoimmune deals by Company A-Z 2010-2015
Appendix 2: Directory of autoimmune deals by stage of development 2010-2015
Appendix 3: Directory of autoimmune deals by deal type 2010-2015
Appendix 4: Directory of autoimmune deals by technology type 2010-2015

Table of figures

Figure 1: Autoimmune partnering since 2010
Figure 2: Big pharma - top 50 - autoimmune deals 2010 to 2015
Figure 3: Big pharma autoimmune deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - autoimmune deals 2010 to 2015
Figure 5: Big biotech autoimmune deal frequency - 2010 to 2015
Figure 6: Active autoimmune dealmaking activity- 2010 to 2015
Figure 7: Autoimmune partnering by deal type since 2010
Figure 8: Autoimmune partnering by industry sector since 2010
Figure 9: Autoimmune partnering by stage of development since 2010
Figure 10: Autoimmune partnering by technology type since 2010
Figure 11: Autoimmune partnering by oncology target since 2010
Figure 12: Autoimmune deals with a headline value
Figure 13: Autoimmune deal headline value distribution, US$million - discovery stage
Figure 14: Autoimmune deal headline value distribution, US$million - preclinical stage
Figure 15: Autoimmune deal headline value distribution, US$million - phase I stage
Figure 16: Autoimmune deal headline value distribution, US$million - phase II stage
Figure 17: Autoimmune deal headline value distribution, US$million - phase III stage
Figure 18: Autoimmune deal headline value distribution, US$million - regulatory stage
Figure 19: Autoimmune deal headline value distribution, US$million - marketed stage
Figure 20: Summary median headline value by stage of development, 2009-2014
Figure 21 Autoimmune deals with upfront payment values
Figure 22: Autoimmune deal upfront payment distribution, US$million - discovery stage
Figure 23: Autoimmune deal upfront payment distribution, US$million - preclinical stage
Figure 24: Autoimmune deal upfront payment distribution, US$million - phase I stage
Figure 25: Autoimmune deal upfront payment distribution, US$million - phase II stage
Figure 26: Autoimmune deal upfront payment distribution, US$million - phase III stage
Figure 27: Autoimmune deal upfront payment distribution, US$million - regulatory stage
Figure 28: Autoimmune deal upfront payment distribution, US$million - marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010-2015
Figure 30: Autoimmune deals with milestone payments
Figure 31: Autoimmune deal milestone distribution, US$million - discovery stage
Figure 32: Autoimmune deal milestone distribution, US$million - preclinical stage
Figure 33: Autoimmune deal milestone distribution, US$million - phase I stage
Figure 34: Autoimmune deal milestone distribution, US$million - phase II stage
Figure 35: Autoimmune deal milestone distribution, US$million - phase III stage
Figure 36: Autoimmune deal milestone distribution, US$million - regulatory stage
Figure 37: Autoimmune deal milestone distribution, US$million - marketed stage
Figure 38: autoimmune deals with royalty rates, %
Figure 39: Autoimmune deal royalty rate distribution, US$million - discovery stage
Figure 40: Autoimmune deal royalty rate distribution, US$million - preclinical stage
Figure 41: Autoimmune deal royalty rate distribution, US$million - phase I stage
Figure 42: Autoimmune deal royalty rate distribution, US$million - phase II stage
Figure 43: Autoimmune deal royalty rate distribution, US$million - phase III stage
Figure 44: Autoimmune deal royalty rate distribution, US$million - regulatory stage
Figure 45: Summary median royalty rate by stage of development, 2010-2015
Figure 46: Top autoimmune deals by value since 2010

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.